GlassScriptPhysician profile
Adelia A Sazonov
NPI 1871930701
$3,217.72
in general payments reported to CMS, 2019-2025
23 companies · $50.24 in 2025
The $50.24 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $15.79 · 2022: $584 · 2023: $1,632 · 2024: $598 · 2025: $50.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.97 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $446.07 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $368.78 | 2019-2023 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.64 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $297.54 | 2019-2024 | Spravato |
| Abbvie INC. | $263.55 | 2022-2024 | Vraylar |
| Lundbeck LLC | $232.45 | 2019-2024 | Rexulti, Brintellix |
| Axsome Therapeutics, INC. | $182.22 | 2022-2023 | Auvelity |
| Indivior INC. | $177.76 | 2019-2024 | Perseris, Sublocade |
| Corium, LLC | $134.84 | 2022-2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $133.77 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $132.35 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $108.71 | 2022-2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $78.53 | 2023-2024 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $69.91 | 2019-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $52.98 | 2022-2023 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $47.91 | 2023-2024 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $41.39 | 2023-2024 | Quviviq |
| Gilead Sciences, INC. | $21.53 | 2019 | |
| Noven Therapeutics, LLC | $19.54 | 2024 | Xelstrym, Secuado |
| Azurity Pharmaceuticals, INC. | $17.09 | 2023 | Horizant |
| Acadia Pharmaceuticals INC | $15.36 | 2022 | |
| Neuronetics, INC. | $13.80 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,567.95 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelia Sazonov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.